Get the Stockscreener App
0.00
100.00%
-6.75
Athira Pharma Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
See More
Previous Close:
$6.75
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$26.62M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
0.00
EPS:
-3.09
Net Cash Flow:
$-101.06M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$8.36
Athira Pharma Inc Stock (ATHA) Company Profile
Name
Athira Pharma Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare ATHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.00 | 26.62M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.08 | 111.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.78 | 77.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
809.64 | 49.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
355.53 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
334.28 | 37.42B | 4.98B | 69.59M | 525.67M | 0.5197 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Athira Pharma Inc Stock (ATHA) Latest News
Signal Recap: Will Athira Pharma Inc outperform during market ralliesJuly 2025 Chart Watch & Long Hold Capital Preservation Tips - baoquankhu1.vn
Smart Money: Is Athira Pharma Inc a play on infrastructure spendingBreakout Watch & Verified Momentum Watchlists - baoquankhu1.vn
Aug Sectors: Is Macys Inc a potential multi bagger2025 Dividend Review & High Win Rate Trade Tips - baoquankhu1.vn
Aug Macro: What is the long term forecast for Athira Pharma Inc stockMarket Growth Summary & Weekly High Return Stock Forecasts - baoquankhu1.vn
Patterns Watch: Whats the beta of Athira Pharma Inc stockBear Alert & Short-Term Swing Trade Alerts - baoquankhu1.vn
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA" - Investing News Network
Athira Pharma, Inc. (NASDAQ:ATHA) Sees Significant Growth in Short Interest - Defense World
Athira Pharma (ATHA) Options to Be Delisted on January 12th - GuruFocus
Why retail investors favor Athira Pharma Inc. stockPortfolio Profit Report & Fast Entry and Exit Trade Plans - Улправда
Athira Pharma Reports Reduced Losses Amid Cost Cuts - MSN
LONA Stock Price, News & Analysis - Stock Titan
Athira Pharma Rebrands as LeonaBio, Refocusing on Oncology - TipRanks
Athira Pharma announces name change to LeonaBio - TipRanks
Athira Pharma changes name, ticker symbol - MSN
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy - Investing.com Nigeria
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy By Investing.com - Investing.com South Africa
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker 'LONA” - The Manila Times
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” - Chartmill
Trade Report: How strong is Athira Pharma Inc. stock balance sheetGDP Growth & Expert Verified Stock Movement Alerts - moha.gov.vn
Bull Run: Can Athira Pharma Inc. stock sustain revenue growthTrend Reversal & Free High Accuracy Swing Entry Alerts - Улправда
How analysts rate Athira Pharma Inc. stock todayWatch List & Stepwise Swing Trade Plans - ulpravda.ru
Will Athira Pharma Inc. stock continue upward momentumJuly 2025 Volume & Weekly Watchlist for Hot Stocks - Улправда
Can Athira Pharma Inc. stock sustain revenue growthQuarterly Profit Summary & Low Risk Entry Point Guides - ulpravda.ru
How sustainable is Athira Pharma Inc. stock dividend payoutMarket Sentiment Report & Community Consensus Picks - ulpravda.ru
Athira Pharma, Inc.Common Stock (NQ: ATHA - FinancialContent
Quarterly Trades: How sustainable is Athira Pharma Inc. stock dividend payoutJuly 2025 PreEarnings & Accurate Buy Signal Notifications - Улправда
Athira Pharma shares surge after securing rights to phase 3 breast cancer therapy - MSN
Athira Pharma (NASDAQ:ATHA) CEO Mark James Litton Sells 2,586 Shares - Defense World
Athira Pharma (NASDAQ:ATHA) Insider Martin Javier San Sells 1,644 Shares of Stock - Defense World
Worthington, Athira Pharma general counsel, sells $6k in ATHA stock - Investing.com Canada
Athira Pharma CSO Church sells $6k in ATHA stock By Investing.com - Investing.com Australia
Athira Pharma CSO Church sells $6k in ATHA stock - Investing.com
Aug Analyst Calls: How 1CM Inc IQ70 stock performs during market turbulence2025 Retail Activity & Short-Term Trading Opportunity Alerts - moha.gov.vn
Immix Biopharma (NASDAQ:IMMX) & Athira Pharma (NASDAQ:ATHA) Critical Survey - Defense World
EDGAR Filing Documents for 0001193125-25-323692 - SEC.gov
Athira Pharma Stock Rockets 92% With 5-Day Winning Streak - Trefis
Athira Pharma Licenses Lasofoxifene For Metastatic Breast Cancer, Secures $236 Million Funding - Voice Of HealthCare
Athira Pharma recovers from Alzheimer’s failure with breast cancer pivot and $90M investment - MSN
How strong is Athira Pharma Inc. stock balance sheetMarket Sentiment Report & Weekly High Return Stock Opportunities - bolumsonucanavari.com
Can Athira Pharma Inc. stock beat analyst upgradesTrade Signal Summary & Precise Buy Zone Identification - Улправда
Does Athira Pharma Inc. stock trade at a discount to peersJuly 2025 Big Picture & Daily Volume Surge Signals - Улправда
Volume Summary: Why retail investors favor Athira Pharma Inc. stockJuly 2025 Technicals & AI Powered Market Entry Ideas - Улправда
Athira Pharma Inc. (ATHA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Mizuho maintains Neutral on Athira Pharma stock after transformative deals By Investing.com - Investing.com Canada
Athira Pharma stock soars after acquiring rights to Phase 3 breast cancer drug - Investing.com Australia
Will Athira Pharma Inc. stock benefit from automationWeekly Stock Recap & Reliable Price Action Trade Plans - Улправда
Athira Pharma raises $90 million as Bothell firm shifts focus - The Business Journals
Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast CancerSlideshow (NASDAQ:ATHA) 2025-12-18 - Seeking Alpha
Finance Watch: Athira Licenses Breast Cancer Drug, Raises Cash To Develop It - Citeline News & Insights
Ligand Pharmaceuticals (NASDAQ: LGND) outlines Athira investment update and disclosure channels - Stock Titan
Athira Pharma, Inc. (ATHA) Stock: Rockets 68% After Phase 3 Lasofoxifene Deal and $90M Private Placement - parameter.io
Athira Pharma Inc Stock (ATHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.85%
1.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):